ArriVent BioPharma, Inc. AVBP Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s short- and long-term operating lease liabilities?
- ArriVent BioPharma, Inc. (AVBP) reported short- and long-term operating lease liabilities of $47K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s short- and long-term operating lease liabilities changed year-over-year?
- ArriVent BioPharma, Inc.'s short- and long-term operating lease liabilities increased by 1275.0% year-over-year, from -$4K to $47K.